Twin Launch by ResMed - Analyst Blog
04 Juni 2013 - 9:30PM
Zacks
Leading provider of medical
equipment for treating and diagnosing sleep disordered breathing
(SDB) ResMed Inc. (RMD) recently launched its
Quattro Air full face mask to aid positive airway pressure therapy.
The company will start shipping the breakthrough offering from Jun
7, 2013.
As per management, the company spent over $100 million in research
and development expenditure in 2012 to develop this ground breaking
therapeutic mask. ResMed asserts that its Quattro Air full face
mask is the lightest full face mask currently available in the
market. With a weight of 3.3 ounces, the Quattro mask is 45%
lighter than the Mirage Quattro mask. Mirage is the earlier version
manufactured by the company and is presently the best selling full
face mask in the U.S.
The Quattro air mask includes ResMed’s market leading technology
such as the enhanced dual-wall spring air cushion, flex-wing
forehead support and circular diffuse vent among others. Given its
innovative technology and light weight, the Quattro air mask should
witness rising sales uptake following its market launch.
In a parallel announcement, ResMed launched SleepSeeker online tool
to increase patient engagement in therapy. The online tool is
hosted on the company’s online patient support community
WakeUptoSleep.com.
The SleepSeeker tool enables patients using ResMed’s S9 series air
flow generators to track their therapy data as well as any apnea or
hypoapnea events for further corrective action. Thus, this online
tool improves patient involvement and engagement in the
therapy.
ResMed currently holds a major position in the worldwide market for
generators, masks, and related accessories for the treatment of
SDB, especially obstructive sleep apnea (OSA). The company enjoys a
competitive edge over other players in the market it serves.
Considering the SDB market overview, there is massive growth
opportunity driven by lifestyle trends, further penetration and
increasing awareness. The recent developments reflect ResMed’s
undertaking to foster growth on the back of innovation, increasing
awareness and patient engagement. The launch of the Quattro air
mask should improve sales of the company’s mask franchise which
faced a slowdown in the third quarter.
While the international market still offers some of the biggest
growth opportunities for ResMed, the unfavorable economic
environment in Europe remains an overhang. The stock carries a
Zacks Rank #3 (Hold).
While we have a neutral stance on ResMed, other medical stocks such
as Conceptus Inc. (CPTS), Haemonetics
Corporation (HAE) and Cyberonics Inc.
(CYBX) are likely to do well. These stocks carry a Zacks Rank #1
(Strong Buy).
CONCEPTUS INC (CPTS): Free Stock Analysis Report
CYBERONICS INC (CYBX): Free Stock Analysis Report
HAEMONETICS CP (HAE): Free Stock Analysis Report
RESMED INC (RMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Conceptus, Inc. (MM) (NASDAQ:CPTS)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Conceptus, Inc. (MM) (NASDAQ:CPTS)
Historical Stock Chart
Von Sep 2023 bis Sep 2024
Echtzeit-Nachrichten über Conceptus, Inc. (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Conceptus, Inc. (MM) News-Artikel